


DOCKET No.:

TORQ-0002 (103336.00004)



PATENT SIGN

AUG 0 8 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UECE

AUG 0 9 2002

TECH CENTER 1000

Applicants:

Robert F. Hofmann, et al.

Serial No.:

09/822,773

Filed:

March 30, 2001

Art Unit:

1614

Examiner:

John D. Pak

For:

USES OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION

IN ARTERIOSCLEROSIS

Commissioner for Patents

Box: NON-FEE AMENDMENT

Washington, D. C. 20231

Sir:

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

August 2, 2002.

Debra A. Peppe

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed July 2, 2002, Applicants hereby elect, without traverse, to prosecute in this application the following disclosed species:

- (i) "peroxidic species" or reaction product from oxidation of alkene, wherein the alkene may be, for example, geranylgeraniol;
 - (ii) penetrating solvent such as DMSO;
 - (iii) dye containing chelated divalent or trivalent metal such as porphyrin; and





TORQ-0002 DOCKET No.: (103336.00004) **PATENT**

(iv) aromatic redox compound such as benzoquinone.

Respectfully submitted,

T. Ling Chwang

Reg. No. 33,590

Jackson Walker L.L.P.

2435 North Central Expressway, Suite 600

Richardson, Texas 75080

Tel: (972) 744-2919 Fax: (972) 744-2909

August 2, 2002